SCHEMBL23960906

SCHEMBL23960906

CC(C)(C)OC(=O)Nc1ccc(-c2cncs2)cc1NC(=O)c1ccc(N2CCN(C(=O)OC(C)(C)C)CC2)cn1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.51
MEN1 O00255 1/20 0.51
MAPT P10636 1/20 0.51
TSHR P16473 1/20 0.51
KMT2A Q03164 1/20 0.51
HDAC3 O15379 5/20 0.49
GPR119 Q8TDV5 2/20 0.47
WNT3A P56704 1/20 0.45
KCNH2 Q12809 2/20 0.45
CYP1A2 P05177 1/20 0.45
CYP2C18 P33260 1/20 0.45
CYP2C19 P33261 1/20 0.45
HDAC2 Q92769 4/20 0.43
BACE1 P56817 1/20 0.42
ALK Q9UM73 3/20 0.41
ATR Q13535 1/20 0.39
HTT P42858 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
CCNK O75909 1/20 0.39
CCNA2 P20248 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21275921 0.90 HDAC3 (0.62) SMN1; SMN2MEN1MAPTTSHRKMT2A
SCHEMBL20181660 0.89 KCNH2 (0.58) SMN1; SMN2MEN1MAPTTSHRKMT2A
SCHEMBL20181718 0.88 HDAC3 (0.57) SMN1; SMN2MEN1MAPTTSHRKMT2A
SCHEMBL23960936 0.88 MEN1 (0.54) SMN1; SMN2MEN1MAPTTSHRKMT2A
SCHEMBL20163065 0.87 HDAC2 (0.54) SMN1; SMN2MEN1MAPTTSHRKMT2A
SCHEMBL20163064 0.87 MEN1 (0.51) SMN1; SMN2MEN1MAPTTSHRKMT2A
SCHEMBL20181517 0.85 HDAC2 (0.55) SMN1; SMN2MEN1MAPTTSHRKMT2A
SCHEMBL20163050 0.85 HDAC3 (0.60) SMN1; SMN2MEN1MAPTTSHRKMT2A
SCHEMBL20163093 0.85 HDAC3 (0.60) SMN1; SMN2MEN1MAPTTSHRKMT2A
SCHEMBL23961031 0.84 HDAC3 (0.62) HDAC3KCNH2CYP1A2CYP2C18CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210332036-A1 PYRIMIDINE AND PYRAZINE HDAC1,2 INHIBITORS REGENACY PHARMACEUTICALS LLC (US) 2021-10-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210332036-A1 PYRIMIDINE AND PYRAZINE HDAC1,2 INHIBITORS HDAC1, HDAC2, HDAC11 SMN1; SMN2 1802/4885MEN1 4613/4885MAPT 1952/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.